Harnessing regulatory T cells to establish immune tolerance

Author:

Ho Patrick1ORCID,Cahir-McFarland Ellen2ORCID,Fontenot Jason D.3ORCID,Lodie Tracey4ORCID,Nada Adel5,Tang Qizhi1678ORCID,Turka Laurence A.9,Bluestone Jeffrey A.10ORCID

Affiliation:

1. Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA.

2. Abata Therapeutics, Boston, MA 02472, USA.

3. Sangamo Therapeutics, Brisbane, CA 94005, USA.

4. Quell Therapeutics, London W12 OBZ, UK.

5. GentiBio, Cambridge, MA 02140, USA.

6. Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA.

7. Gladstone Institute of Genomic Immunology, University of California San Francisco, San Francisco, CA 94143, USA.

8. Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA 94143, USA.

9. Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.

10. Sonoma Biotherapeutics, South San Francisco, CA 09080, USA.

Abstract

Engineered regulatory T (T reg ) cells have emerged as precision therapeutics aimed at inducing immune tolerance while reducing the risks associated with generalized immunosuppression. This Viewpoint highlights the opportunities and challenges for engineered T reg cell therapies in treating autoimmune and other inflammatory diseases.

Publisher

American Association for the Advancement of Science (AAAS)

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3